STORM Therapeutics to present promising Phase 1 sarcoma data demonstrating activity of first‑in‑class METTL3 inhibitor STC‑15 at ASCO 2026
Subset analysis shows early clinical activity supported by biomarker evidence of targeting cancer stem cell pathways driving tumor growth and progression
22 May 2026, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the clinical stage company targeting RNA modifications to reprogram cells and develop novel cancer therapies, today announces that a subset analysis of sarcoma patients enrolled in the Phase 1 dose escalation study of its lead candidate, STC‑15, will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 – June 2, 2026 in Chicago, Illinois.
